In liver cancer, high expression of CD96 is closely associated with deterioration and shorter disease-free survival (DFS) and OS times in patients, and it is accompanied by a low efficacy of antitumor immunotherapy (Sun et al., 2019). This evidence concerns the gene CD96 and liver cancer.